Enzyme in Medical Technology

Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease

Baby Girl with Hypophosphatasia Treated With ENB-0040 at Children's Hospital, Health Sciences Centre in Winnipeg MONTREAL, Dec. 1 /PRNewswire/ -- Enobia Pharma, an emerging Canadian biotech company focused on developing novel therapeutics for serious bone disorders, today announced that t...

Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia

MONTREAL, Aug. 20 /PRNewswire/ -- Enobia Pharma, an emerging biotech company focused on developing novel therapeutics for serious bone disorders, today announced that the first patient in its clinical program for hypophosphatasia has been dosed. Enobia is investigating Enzyme Replacement Thera...

Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models

- Systemic treatment with chemotherapy and pegylated enzyme produces significantly enhanced survival compared to chemotherapy alone - - Pegylated enzyme well tolerated - SAN DIEGO, July 22 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharma...

Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference

- Data Support Intravenous to Subcutaneous Conversion - SAN DIEGO, April 16 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced new pre-clinical f...

Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms

NEW YORK, Aug. 14 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM ) commented today on a recent paper published in Nucleic Acids Research by a group of researchers at the National Cancer Institute on the ability of furamidine to inhibit a key enzyme involved in the DNA repa...

Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme

SAN DIEGO, Dec. 10 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced the commenceme...

New Insight Into the Controls on a Go-To Enzyme

St. Jude scientists report basic findings on critical enzyme's regulation may hold key to understanding how to better treat an array of disorders MEMPHIS, Tenn., Nov. 19 /PRNewswire-USNewswire/ -- Scientists at St. Jude Children's Research Hospital have gained new insights into regulatio...

Viral Enzyme Recruited in Fight Against Ear Infection

St. Jude Study Success in Using Virus Enzyme to Treat Mouse Model of Acute Otitis Media Suggests that Nasal Spray Could Be Used to Prevent Both Ear Infection and Pneumonia in People with Influenza MEMPHIS, Tenn., March 22, 2007 /PRNewswire/ -- Parents might one day give their children a weekly tre...

Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2 Predicts Heart Disease Risk in Metabolic Syndrome Patients

NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Study results show that elevated lipoprotein-associated phospholipase A2 (Lp-PLA2), a cardiovascular-specific inflammatory enzyme associated with unstable plaque that can lead to heart attack and stroke, is especially predictive of heart disease risk in ...

AGI Dermatics Data Shows the 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1 and TNF-alpha in UV Irradiated Skin Cells

Clinical Data Presented at the Society for Investigative Dermatology FREEPORT, N.Y., May 16, 2007 /PRNewswire-FirstCall/ -- AGI Dermatics today announced new clinical research that the 8-oxo-guanine DNA glycosylase (OGG1) encapsulated in liposomes enhances DNA repair and reduces MMP-1 and TNF-alph...

NIEHS Researchers Identify Enzyme Critical in DNA Replication

BETHESDA, Md., July 5, 2007--In this weeks issue of Science, researchers from the National Institute of Environmental Health Sciences (NIEHS) and Umeö University in Sweden report an important discovery about a critical new role that an enzyme called DNA polymerase epsilon plays in replicating...

Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome

...ed for effective, well tolerated therapies for MDS having novel mechanisms of action. TELINTRA has a novel mechanism of action that inhibits a target enzyme called glutathione S- transferase P1-1 which in turn facilitates the activation of JNK kinase, a key regulator of cellular growth and differentiation ...

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

...three Phase III studies of velaglucerase alfa, its enzyme replacement therapy in development for the treatme... proprietary technology, in a human cell line. The enzyme produced has the exact human amino acid sequence a...ow. Gaucher Disease results from a specific enzyme deficiency in the body, caused by a genetic mutati...

Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk

...the breast cancer drug. Paxil, Prozac and Zoloft are among a group of antidepressant drugs known as CYP2D6 inhibitors. These drugs prevent the CYP2D6 enzyme from working properly, and cause less of the active form of tamoxifen, called endoxifen, from being produced, making the drug less effective at preven...

Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA

... About LX1032 LX1032 was discovered and developed at Lexicon to reduce serotonin production by inhibiting tryptophan hydroxylase (TPH), a key enzyme in the synthesis of serotonin. Excessive levels of serotonin have been implicated in symptoms associated with carcinoid syndrome. Serotonin's breakd...

FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent

... Tekturna, a direct renin inhibitor, is the only drug that works by directly targeting renin and decreasing the activity of the RAAS. Renin is an enzyme produced by the kidneys that starts a process that makes blood vessels narrow and, when inappropriately activated, may lead to high blood pressure. Te...

UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201

...approval of what appears so far to be a well tolerated and effective therapy." BSI-201 targets PARP, or poly (ADP-ribose) polymerase, a key enzyme involved in DNA repair and cell proliferation. By inhibiting the enzymatic activity of PARP, BSI-201 significantly enhances the anti-tumor effects of ...

New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed

...ived once-daily nevirapine, 2.1 percent in patients who received twice-daily nevirapine and 0.0 percent in patients who received ATV/r. Rates of liver enzyme elevations were 5.9 percent in patients who received once-daily nevirapine, 7.4 percent in patients who received twice-daily nevirapine and 1.6 percen...

Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome

...ve metabolite have demonstrated reductions in blood pressure, triglycerides, cholesterol levels, C-reactive protein, and fasting blood glucose levels. enzyme levels indicative of liver damage, such as ALT and AST, are decreased, pointing to an outstanding safety profile. Increases in HDL, the "good" cholest...

BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza

... possible in Japan. About Peramivir Peramivir is an anti-viral agent that inhibits the interactions of influenza neuraminidase, an enzyme which is critical to the spread of influenza within a host. Peramivir has demonstrated clinical activity and safety in prior human studies. In laborat...

Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease

...g Administration (FDA) for velaglucerase alfa, its enzyme replacement therapy in development for the treatme... proprietary technology, in a human cell line. The enzyme produced has the exact human amino acid sequence a...ow. Gaucher Disease results from a specific enzyme deficiency in the body, caused by a genetic mutati...

Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease

...d a treatment protocol for velaglucerase alfa, its enzyme replacement therapy in development for the treatme... proprietary technology, in a human cell line. The enzyme produced has the exact human amino acid sequence a...ow. Gaucher Disease results from a specific enzyme deficiency in the body, caused by a genetic mutati...

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease

... enroll approximately 60 subjects who are naive to enzyme replacement therapy (ERT) or who have not received...ales and females with Fabry disease as compared to enzyme replacement therapy (ERT). The Agency agrees that...eatment resulted in increased levels of the target enzyme (a-Gal A), as measured in white blood cells and in...

VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease

...ing suggestions from the Agency on the Company's Phase 3 trial design. VIA-2291 is a selective and reversible inhibitor of 5 Lipoxygenase, a key enzyme in the biosynthesis of leukotrienes, which are important mediators of the inflammation believed to be involved in the development and progression of a...

FDA Advisory Committee Votes in Favor of Zyprexa for Two Adolescent Indications

... with Zyprexa were similar to those seen in adults. The incidence and magnitude of changes in weight, prolactin, triglyceride, cholesterol and hepatic enzyme levels were greater in adolescents than adults. Sedation was also more common in adolescents than adults. "Because weight gain and some of the me...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

...urred early during treatment and improved or resolved during treatment. Permanent treatment discontinuation due to AEs resulted from infections, liver enzyme increases and fully reversible central nervous system events. "The observation of high response rate and durable objective responses indicates t...

Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival

...otherapy, in patients with metastatic triple-negative breast cancer (TNBC). BSI-201 is a novel investigational agent that acts by inhibiting PARP1, an enzyme that repairs DNA damage. In this study, 116 women with metastatic TNBC, defined as tumors lacking expression of estrogen and progesterone recep...

Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting

...safety and biological effects of restoring SERCA2a enzyme activity in heart muscle cells. The enzyme levels are decreased in late stages of heart failu...y of the heart to contract properly. Replacing the enzyme may restore function and reverse heart failure. ...

Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy

...t Safety Profile and Biological Effects of SERCA2a enzyme Replacement SAN DIEGO, May 26 /PRNewswire/ --...nounced that results from its genetically targeted enzyme replacement therapy for advanced heart failure, in...nning of heart failure is the depletion of SERCA2a enzyme in heart muscle cells, which results in abnormal i...

Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection

...alth officials. About Fidaxomicin Fidaxomicin is the first in a new class of antibiotics called macrocyclics, which inhibit the bacterial enzyme RNA polymerase, resulting in the death of Clostridium difficile . The narrow spectrum profile of fidaxomicin may eradicate Clostridium difficile se...

Quest Diagnostics Introduces First Commercial Laboratory Test for Identifying the H1N1 Swine Flu Virus

...oratory, perform a broad range of testing services to detect Influenza viruses, including PCR, rapid cell culture, direct immunofluorescence (DFA) and enzyme immunoassay (EIA) techniques. Depending on the laboratory, the company can perform testing on different types of collected specimens, such as nasophar...

Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome

...f varespladib or matching placebo. Varespladib is a potent and highly selective oral inhibitor of secretory phospholipase A2 (sPLA2), an inflammatory enzyme implicated in ACS, vascular inflammation, atherosclerosis and adverse lipid profiles. The pre-specified primary endpoint analysis was conducted w...

Isis and Collaborators Present New Research at the ATVB Annual Conference

...antisense inhibition of 11 beta-HSD1 reduced triglycerides in both liver and blood, while also reducing body fat in animal models. 11 beta-HSD1 is an enzyme that inactivates steroids and may contribute to metabolic disease, suggesting the potential therapeutic benefit of antisense drugs inhibiting 11 beta-...

Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia

...H, either D-3263, finasteride (an inhibitor of the enzyme 5-alpha-reductase) or a combination of the two age...ide is a known inhibitor of 5-alpha reductase, the enzyme that converts testosterone to DHT, D-3263 is not an inhibitor of this enzyme suggesting that the two agents may act by differen...

BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome

...in has developed and manufactures two FDA-approved enzyme replacement therapies, one for the treatment of MP...fe-threatening conditions caused by the underlying enzyme deficiency. The incidence estimates for MPS I...ent and planned pre-clinical trials related to the enzyme replacement therapy for MPS IVA; the content and t...

Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma

...ther Pharmacyclics Btk inhibitors are being developed for application to autoimmune and inflammatory diseases. Bruton's tyrosine kinase is a critical enzyme involved in B-cell activation and function, and inhibition may be useful in the treatment of a number of immune mediated diseases. B-cells are a type...

Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin

...ual property protection for fidaxomicin." Fidaxomicin is the first in a new class of antibiotics called macrocyclics, which inhibit the bacterial enzyme RNA polymerase, resulting in the death of Clostridium difficile . The narrow spectrum profile of fidaxomicin may eradicate Clostridium difficile se...

Discovery of Marker for Colon Stem Cells Could Shed Light on What Drives Tumor Growth

...gy at the Helen F. Graham Cancer Center of the Christiana Care Health System, and a faculty member at the University of Delaware , have discovered an enzyme common to both normal and malignant colon stem cells that will assist scientists searching for a cure for colon cancer. (Logo: http://www.newsc...

CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis

...sed to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) th...

CRESTOR(R) Reduced Risk of Blood Clots in the Veins

...sed to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) th...